Home Merck to Present New Data for KEYTRUDA (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting
 

Keywords :   


Merck to Present New Data for KEYTRUDA (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting

2016-04-06 14:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Data Evaluating KEYTRUDA as a Single Agent and in Novel Combinations Across a Wide Range of Cancers to Be Presented KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new research investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in multiple tumor types, both as a single agent and in combination with other therapies, will be presented at this years American Association for Cancer Research (AACR) Annual Meeting in New Orleans, April 16 20. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestor:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data research present american

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
24.11Costume
24.11BB S604ULS
24.1133
24.11 ElectronicAudioExperimentsDude Incedible
24.11 TC101 5IP 6 NS.NEO 950GH S
24.11
24.11
24.11
More »